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Of the diverse array of putative molecular and biological functions assigned
to long non-coding RNAs (lncRNAs), one attractive perspective in epigenetic
research has been the hypothesis that lncRNAs directly interact with the
proteins involved in the modulation of chromatin conformation. Indeed,
epigenetic modifiers are among the most frequent protein partners of
lncRNAs that have been identified to date, of which histone methyltransfer-
ases and protein members of the Polycomb Repressive Complex PRC2 have
received considerable attention. This review is focused on how lncRNAs
interface with epigenetic factors to shape the outcomes of crucial biological
processes such as regulation of gene transcription, modulation of nuclear
architecture, X inactivation in females and pre-mRNA splicing. Because of
our increasing knowledge of their role in development and cellular differen-
tiation, more research is beginning to be done into the deregulation of
lncRNAs in human disorders. Focusing on cancer, we describe some key
examples of disease-focused lncRNA studies. This knowledge has signifi-
cantly contributed to our ever-improving understanding of how lncRNAs
interact with epigenetic factors of human disease, and has also provided a
plethora of much-needed novel prognostic biomarker candidates or poten-
tial therapeutic targets. Finally, current limitations and perspectives on
lncRNA research are discussed here.
This article is part of a discussion meeting issue ‘Frontiers in epigenetic
chemical biology’.1. Introduction
While less than 2% of the human genome has protein-coding potential,
over 70% of it can undergo transcription, meaning that most of the human
transcriptome consists of non-coding RNA (ncRNA) [1]. The non-coding
transcriptome can be conceptualized in terms of the varying sizes of non-
coding transcripts, ranging from the shorter miRNAs and piRNAs of
below 40 bp, through mid-sized snoRNAs (60–300 bp) and enhancer RNAs
(eRNA; 50–2000 bp) [2], to long non-coding RNAs (lncRNAs), a highly
diverse group of transcripts that are all over 200 bp in length [3]. These can
be further stratified into long intergenic ncRNA (lincRNAs), transcribed
ultra-conserved regions (T-UCRs), natural antisense transcripts (NATs) and
large intronic ncRNAs, among others. In quantity, lncRNAs outnumber
protein-coding genes, yet it remains the case that relatively few of the nearly
60 000 human lncRNA genes [4] have been studied and characterized in sig-
nificant detail. Nonetheless, over the past two decades, they have been
linked to a wide range of molecular biological processes, ranging from
nucleus-specific roles in modulating transcription, epigenetic modification,
Table 1. Examples of long non-coding RNAs that directly interact with histone modifiers and chromatin-associated proteins.
lncRNA functional effects references
Xist histone modification complex recruitment






HOTAIR histone modification complex scaffolding
histone modification (H3K4 demethylation, H3K27me3)
gene silencing
[15 – 17]
ANRIL PcG histone modification complex recruitment
histone modification (H3K27me3; H2AK119ub)
gene silencing
[18,19]
KCNQ1OT1 histone modification complex recruitment (G9a, PRC2)

















Dali trans inhibition of DNMT1
gene activation
[27]
lincRNA-p21 hnRNP-K interaction; DNMT1 interaction
p53 target gene silencing
[28,29]
Firre nuclear architecture remodelling
escape from X inactivation
[7]
MALAT1 nuclear body formation
splicing factor sequestration
localization to sites of active transcription
[30,31]







DNA looping and nuclear compartment formation, to
involvement in alternative splicing and miRNA network
cross-talk [5].2. Long non-coding RNA cross-talk with
epigenetic factors
Of the functions assigned to lncRNAs, perhaps the crucial
one from the perspective of epigenetics researchers has
been the hypothesis that lncRNAs directly interact with the
writers, readers and erasers of histones [6]. Thus, lncRNAsmay direct and determine the specific subnuclear domains
and genetic loci at which the histone-modifying machinery
acts in any given cell type [7]. They could also serve as
molecular scaffolds of specific chromatin-regulatory com-
plexes, combining and integrating the molecular functions
of multiple histone modifiers along with other types of
chromatin-regulatory machinery, thereby fine-tuning both
the lower- and higher-order chromatin structure of a
given target locus [8]. This section, summarized in table 1,
will provide an overview of how lncRNAs shape the out-





33. Long non-coding RNA association with
epigenetic modification and transcriptional
regulation
The origins of the hypothesis that lncRNAs guide histone
modifiers to modulate the epigenetic control of gene
transcription can be traced back to earlier breakthrough
studies on the process of X chromosome inactivation (XCI)
[9,35]. Wutz et al. [10] first found that an ORFless transcript,
termed Xist, is transcribed from the X-inactivation centre
(Xic) and retained in the nucleus to act as the master
cis-acting regulator of XCI. Convergently, Polycomb Repres-
sive Complex 2 (PRC2) was found to be responsible for
H3K27me3 enrichment in the Xi [36], and PRC2 recruitment
to the Xi was shown to depend on Xist expression [37].
From these findings emerged the idea that Xist may
guide PRC2-mediated gene repression on the Xi. Recent
studies characterizing the Xist complex led to the definition
of a stepwise model of the Xist molecular mechanism of
XCI coordination [8]. This silencing process involves
interactions with several chromatin remodelers, including
the DNA-/RNA-binding protein SAFA, the binding protein
SHARP and histone deacetylase 3 (HDAC3) and PRC1/
PRC2 complexes [11,15,38].
As the decade progressed, interest in the idea of RNA-
guided gene regulation broadened following a study on
HOX gene transcriptional regulation [16]. Rinn et al. [16]
demonstrated that an lncRNA transcribed from the HOXC
locus, named HOTAIR, represses the HOXD locus in trans
and in doing so recruits PRC2 to the locus to establish repres-
sive chromatin mark H3K27me3. Tsai et al. [39] later observed
that HOTAIR directly interacts not only with PRC2 at its
50-end but also with H3K4-targeting demethylase LSD1. In
parallel, two independent studies found that PRC2 alone
binds to approximately 24% of transcripts genome-wide,
demonstrating that a genome-wide RNA family may direct
PRC2 to its target genes. These findings widened the scope
of the hypothesis of lncRNA involvement in modulating
chromatin modifications, establishing its potential as a
global epigenetic regulatory mechanism [18,40].
Another functionally related lncRNA implicated in the
epigenetic control of gene expression is known as ANRIL
[19]. It is transcribed antisense to the INK4b(p15)-ARF(p14)-
INK4a(p16) cluster of tumour suppressor genes, a locus
subject to stringent regulation by both PRC1 and PRC2 com-
ponents. Upon its transcription, ANRIL is thought to act in cis
to recruit PRC2 via direct binding to the SUZ12 subunit to
direct H3K27 trimethylation of the locus. ANRIL also recruits
PRC1 by interacting with its CBX7 subunit, and CBX7 in turn
binds H3K27me3, which stimulates H2AK199 ubiquitination
by PRC1 [19,41].
The imprinted lncRNA KCNQ1OT1 was found to interact
with PRC2 components EZH2 and SUZ12, as well as with
G9a, to mediate in cis silencing of a 200 kb locus surrounding
its transcription site in a lineage-specific manner [20]. Partial del-
etion of an 890 bp region of KCNQ1OT1 on the paternal allele,
from which the lncRNA itself is exclusively expressed, resulted
in the loss of paternal allele-specific gene repression of ubiqui-
tously imprinted locus genes and reduced CpG methylation
of the differentially methylated regions of these genes. It has
been proposed to mediate paternal-specific Kcnq1 locus methyl-
ation by interacting with DNA methyltransferase 1 (DNMT1),as DNMT1 occupies the same ubiquitously imprinted
genes and the 890 bp region of KCNQ1OT1 was shown to be
necessary for co-immunoprecipitation of KCNQ1OT1 with
DNMT1 [22].
lncRNA Air is another imprinted lncRNA specifically
expressed from the paternal allele [25]. It is transcribed
antisense to Igf2r and in embryos is necessary for the
repression of Igf2r in cis, as well as for Slc22a2 and Slc22a3
silencing in the placenta. Air was found to preferentially
accumulate at the Slc22a3 promoter in mouse placental
tissue [25]. It interacts with G9a, a necessary factor for
Slc22a3 silencing; thus, Air appears to recruit G9a to target
H3K9 methylation at the promoter, thereby repressing
Slc22a3 expression [25].
A further locus-specific example of ncRNA-modulated
gene silencing was revealed in a study by Wang et al. [24],
in which it was found that ncRNA transcribed upstream of
the CCND1 gene upon DNA damage induction recruits
TLS (Translocated in Liposarcoma) to the promoter region
and allosterically releases it from its inactive conformation,
enabling it to inhibit histone acetyltransferase (HAT) CBP/
p300 and thus repress CCND1 transcription [24].
As for lncRNAs with potential roles in mediating gene
activation, the best example, to date, is perhaps HOTTIP,
which is transcribed from the HOXA locus and is responsible
for the activation of several HOXA genes through the recruit-
ment of the WRD5/MLL histone methyltransferase (HMT)
complex, which in turn facilitates gene activation by tri-
methylating H3K4 at the HOXA promoter [42]. Recently,
eRNAs have also been found to interact with the CBP/p300
HAT complexes bound to enhancers, stimulating CBP HAT
activity to increase H3K27ac levels at both the enhancer
and the promoter of its target gene, which leads to target
gene expression activation [26].
In addition to mediating histone modification, lncRNAs
have also been found to directly influence DNA methylation.
A novel lncRNA that is sense-transcribed from upstream of
the CEPBA gene and that also encompasses the entire
protein-coding mRNA sequence but itself remains in the
nucleus has been described [28]; thereafter, it was called
‘extra-coding’ CEPBA (ecCEPBA), and it was found that it
selectively inhibits DNA methylation of the CEPBA promoter
[28]. This was due to its direct interaction with DNMT1,
which has a higher affinity for ecCEBPA than for the
CEBPA CpG island. Another group identified lincRNA-p21
as a barrier to the reprogramming of pre-induced pluripotent
cells (pre-iPSCs) to iPSCs. LincRNA-p21 is induced by p53
and functions by interacting with H3K9 histone methyltrans-
ferase SETDB1 and with DNMT1. It directs these epigenetic
modifiers to repress pluripotency genes by trimethylating
H3K9 and methylating CpG islands within the target gene
promoters [43].
A particularly unique lncRNA, telomere repeat-contain-
ing RNA (TERRA), is transcribed from telomeres and
regulates telomere maintenance and function through a plur-
ality of integrated mechanisms in a cell cycle-dependent
manner (reviewed in greater depth elsewhere [44,45]).
Among these mechanisms, TERRA has been proposed to
act in part as a scaffold of heterochromatin-associated
proteins at chromosome ends, including Shelterin complex
components TRF1 and TRF2, heterochromatin protein HP1a





44. Long non-coding RNAs involved in nuclear
architecture and three-dimensional genome
structure
Recent proteomic studies of Xist interactors have also made
progress in the mechanistic integration of its base-level epige-
netic cross-talk with their role in the unique rearrangement of
X chromosomal higher-order chromatin structure [8]. While
the active X chromosome (Xa) normally assumes a distinct
three-dimensional structure consisting of several topologically
associated domains, Xi is compacted into two mega-domains
that are fixed to the nuclear lamina, except for several mega-
loops that escape XCI silencing and establish transcriptionally
active foci [33]. Beginning with the establishment of gene
silencing and chromatin compaction at its own locus, Xist
establishes the higher-order restructuring of the Xi by first
spreading to sites immediately proximal to its locus, forming
the compacted, expansive Xist-coated inactive X chromatin ter-
ritory that grows by drawing initially distal transcriptionally
active regions into the silent compartment [33].
Another intriguing recent example of how lncRNAs can
modulate the three-dimensional arrangement of the genome
is Firre, a nuclear-retained lncRNA that localizes to chromatin
both in cis and in trans to form a distinct nuclear compart-
ment that brings into spatial proximity not only target
sequences of the X chromosome but also specific loci from
chromosomes 2, 9, 15 and 17 [47].5. Epitranscriptomics of long non-coding
RNAs—a nascent field
In a recent study providing a first glimpse of a particularly
intriguing novel mechanistic layer of Xist-mediated epige-
netic cross-talk, it was found that Xist reversibly undergoes
N6-adenosine methylation (m6A). This mark is reportedly
added by METTL3 (methyltransferase like 3), which is
recruited to Xist via RNA-binding motif protein 15
(RBMP15) and RBMP15B of the Spen family. m6A marks
on Xist are, in turn, recognized by YTHDC1 (YTH domain
containing 1). All of these components appear necessary for
Xist-mediated gene silencing, as loss of any of these Xist-
interacting proteins leads to the failure of Xist to silence the
Xi [48]. However, the mechanism by which this pathway con-
tributes to achieve Xi silencing is unknown, let alone how it
cross-talks with the other silencing factors recruited by Xist
to initiate and consolidate gene silencing. Therefore, just as
it will be necessary to further examine the post-translational
modification dynamics of Xist-interacting proteins, so too
will it also be important to find new ways of characterizing
the presence and dynamics of lncRNA post-transcriptional
modifications to form a more precise understanding of how
lncRNA cross-talks with epigenetic modifiers.6. Long non-coding RNAs associated with
alternative splicing
Pre-mRNA splicing, which often occurs co-transcriptionally
and sensu stricto post-transcriptionally, is more often than
not a scenario with multiple possible outcomes that can be
mechanistically determined by splice-regulatory factors,histone modifications and chromatin structure [49–51].
Although the molecular processes underlying specific types
of alternative splicing event have been characterized in
greater detail during the past decade, it is by no means
clear how exactly a given splicing outcome is selected and
set in motion for any given transcript. However, in addition
to regulating the transcriptional activity of genes, lncRNAs
can also influence the processing of pre-mRNA [52], and
hence could be key players in determining the specific con-
ditions under which alternative transcript isoforms are
selected. The best example, to date, of the lncRNA influence
on alternative splicing is given by MALAT1 (Metastasis-
Associated Lung Adenocarcinoma Transcript 1), which
forms a type of nuclear sub-compartment known as the
nuclear speckle, and binds various splicing regulatory factors
[53] such as SRSF1 [54] and serine/arginine (SR) splice-
regulatory factors [54]. MALAT1 depletion leads to increased
exon inclusion in most differentially spliced genes identified
and showed similar alternative splicing patterns to cells
with transient SRSF1 overexpression [54]. It has since been
thought that MALAT1, and other splicing factor-interacting
lncRNAs, negatively regulate alternative splicing events by
sequestering specific splicing factors and restricting their
availability to participate in alternative splicing [54,55].
An additional nuclear-retained lncRNA to have emerged
during the past decade as a key non-coding player in the
regulation of alternative splicing is MIAT (Myocardial Infarc-
tion-Associated Transcript) [56] and its mouse homologue
Gomafu. It has been found that Gomafu contains a repeat
splicing-factor 1 (SF1)-binding motif that facilitates its direct
binding to this SF [57], and that oligos mimicking the
Gomafu SF1-binding site delayed the onset of splicing of a
weak branch point [57]. This result is consistent with the pro-
posed role of SF1 as being required for the removal of introns
with suboptimal branch points and with the notion that
Gomafu restricts SF1 from interacting with sub-optimal
branch points. A subsequent study of Gomafu and another
splicing factor, Celf-3, provided further evidence for the
idea that Gomafu may act as a molecular sponge of splicing
factors to restrict their availability in the nucleus, and thereby
either delay the kinetics of the splicing events that they
coordinate or diminish the frequency of their occurrence [58].7. Epigenetic long non-coding RNAs and cancer
Much of the impetus behind the renewed efforts of the past
decade to understand the role of the non-coding genome in epi-
genetic cross-talk has been driven by the ongoing need to better
characterize human pathologies at the molecular level [3].
Focusing on cancer, this section, summarized in table 2, high-
lights some key examples of disease-focused lncRNA studies
that have significantly contributed to our ever-improving
understanding of how lncRNAs cross-talk with epigenetic fac-
tors in health and disease, and have also provided a plethora
of much-needed novel prognostic biomarkers.
One the most well-studied lncRNAs associated with
cancer is HOTAIR. (A comprehensive overview of HOTAIR
involvement in multiple tumour types is provided by Bhan
& Mandal [89].) A pioneering metastatic lung cancer study
by Gupta et al. [59] found that HOTAIR overexpression
increased the invasive capacity of breast cancer cell lines
and increased lung metastasis in mouse xenograft models.
Table 2. Examples of long non-coding RNAs associated with cancer.
lncRNA disease functional effects tumorigenic effects references
HOTAIR breast cancer PRC2 recruitment, chromatin
modification
metastasis [59]














gastric cancer gene silencing EMT activation
metastasis
[63]
colorectal cancer (CRC) PRC2 recruitment, chromatin
modification (H3K27me3)
invasion and metastasis [64]























bladder cancer SUZ12 interaction
mediation of TGF-b-driven metastasis
metastasis [75]







mediation of TGF-b-driven metastasis















cervical cancer PI3 K/AKT pathway activation increased proliferation
migration
[81]














lncRNA disease functional effects tumorigenic effects references




DACOR1 CRC DNMT1 interaction
CpG methylation
gene expression regulation
increased clonogenic potential [85]
TCF7 HCC SWI/SNF complex recruitment
nucleosome remodelling
gene activation
cancer stem cell (CSC) self-renewal [86]





MIAT chronic lymphocytic leukaemia (CLL) not available increased proliferation [87]
neuroendocrine prostate cancer
(NEPC)





Moreover, over 800 genes were newly occupied and
repressed by PRC2 following HOTAIR overexpression,
including genes known to inhibit breast cancer progression.
Indeed, the capacity of HOTAIR to drive breast cancer metas-
tasis was found to depend on the concomitant presence of
intact PRC2 [59]. HOTAIR has also been found to be upregu-
lated in human oral squamous cell carcinoma samples in
association with a worse prognosis score [60]. In the same
study, it was found that HOTAIR enhances metastasis by
repressing E-cadherin expression via its association with
EZH2 [60]. HOTAIR overexpression was also connected
with gastric cancer malignancy and survival outcome in a
study that linked the upregulation of HOXC cluster genes
with high-risk gastrointestinal stromal tumours [63]. A later
study revealed that HOTAIR can also epigenetically regulate
the transcription of miRNAs in driving gastric cancer inva-
sion and metastasis, demonstrating that HOTAIR directly
represses miR34a by PRC2 recruitment [90]. Furthermore,
HOTAIR overexpression has been associated with hepatocel-
lular carcinoma (HCC) progression [65] and its reoccurrence
after liver transplantation [66]. More recently, it has been pro-
posed that HOTAIR may act as an intermediate factor in the
interaction of Snail and EZH2, facilitating Snail recruitment of
EZH2 to specific genomic targets repressed by Snail. Thus,
HOTAIR appears to be the linking factor of this putative
Snail–HOTAIR–EZH2 tripartite epithelial–mesenchymal
transition (EMT)-promoting repressor switch in HCC [67].
Some interesting examples of recent attempts to investigate
the impact of HOTAIR on anti-cancer therapeutic responses
can be seen in two recent studies of platinum agent-based
chemotherapy resistance in ovarian cancer [29,69]. One
study found that HOTAIR overexpression was associated
with poor survival outcomes in patients with carboplatin-
resistant ovarian tumours, and characterized an associated
DNA methylation signature enriched for PcG (Polycomb
Group protein) target genes that correctly, consistently and
independently predicted survival outcome for carboplatin-
treated patients [29]. On the other hand, the study foundthat patients whose tumours were ‘HOTAIR expressors’
preferentially responded to cisplatin chemotherapy, an
unexpected finding that contradicted another cell-based
study demonstrating that HOTAIR overexpression is associ-
ated with cisplatin resistance in an ovarian cancer cell line,
and that HOTAIR knockdown sensitized the cell line to
cisplatin [69].
MALAT1 owes its name to its discovery as an overex-
pressed transcript in non-small cell lung cancer (NSCLC)
metastases that provided an early-stage marker of NSCLC
metastasis risk even before its molecular functions were
characterized [72]. It was later demonstrated to be a necessary
factor in a mouse xenograft model of NSCLC metastasis,
which was proved by employing antisense oligonucleotides
(ASOs) to deplete MALAT1 in the xenograft tumours studied
[73]. This also gave an early indication of the therapeutic
potential of using ASOs against oncogenic lncRNAs in the
treatment of lncRNA-associated disease. Its overexpression
has also been linked with the invasive capacity of metastatic
colorectal cancer cells [91]. Another authoritative study by
Tripathi et al. [92] aiming to explore the mechanisms
by which MALAT1 may drive oncogenesis found that
MALAT1 controls cell cycle progression by modulating cell
cycle gene expression, and that MALAT1 is required for the
G1/S phase and mitotic progression.
Despite it being principally associated with nuclear body
formation and splicing regulation at the fundamental molecu-
lar level, accumulating evidence indicates that MALAT1
overexpression contributes towards metastatic tumours
predominantly through aberrantly coordinating the epigenetic
regulation of gene expression [93]. Moreover, in bladder cancer,
overexpressed MALAT1 promotes TGFb-driven bladder
cancer metastasis by directly interacting with PRC2 subunit
Suz12 to repress E-cadherin expression [75]. Consistent with
these findings, a direct MALAT1–EZH2 interaction has been
implicated in renal cell carcinoma metastasis, as well as in
osteosarcoma, as outlined in a recent study that directly




7to E-cadherin epigenetic repression in this tumour type and
established MALAT1 as a predictive biomarker of poor
survival in osteosarcoma patients [77]. Furthermore, it was
recently found that the association of MALAT1 with EZH2 pro-
moted mantle cell lymphoma development, in which MALAT1
overexpression was linked with reduced overall survival. In
this study, MALAT1 was found to be responsible for repressing
the transcription of cyclin-dependent kinases (CDKs) p21 and
p27, which are also targets of EZH2. The interaction of
MALAT1 and EZH2 was also found to be enhanced
by EZH2 phosphorylation at T350, and the investigators
suggested that a MALAT1-mediated positive feedback loop
may exist that stabilizes the interaction by promoting T350
phosphorylation of EZH2 [79].
In 2009, Guttman et al. [94] found a cluster of differen-
tially expressed lncRNAs associated with the p53-mediated
DNA damage response. One such lncRNA is known as
lincRNA-p21, which was found to be necessary to enact the
transcriptional regulation of a substantial proportion of
p53 target genes [82]. lincRNA-p21 knockdown significantly
increased cell viability by reducing apoptosis, whereas its
overexpression increased apoptosis following DNA damage
induction through direct interaction with the heterogeneous
nuclear ribonucleoprotein K (hnRNP-K). [82]. hnRNP-K and
lincRNA-p21 also displayed overlapping target promoter
occupancy. Therefore, at least in part, lincRNA-p21 may
regulate the expression of its designated branch of the
p53-mediated gene regulation programme by modulating
hnRNP-K localization to lincRNA-p21 target genes [82].
A more recent study revealed a novel tumour suppressor
lncRNA that may constitute another important branch of the
tumour suppressive p53 network [84]. In searching for novel
lncRNAs epigenetically deregulated in cancer, Diaz-Lagares
et al. first identified TP53TG1 as being CpG-hypermethylated
in colon cancer cell line HCT-116. Overexpression of
TP53TG1 in HCT-116 cells had a tumour suppressive effect
both in vitro and in HCT-116-induced mouse tumours that
was dependent on the presence of functional p53. Next,
RNA pulldown of TP53TG1-bound proteins, combined
with mass spectrometry, established that it binds YBX1, a
protein with both DNA- and RNA-binding capacity that
can participate directly in the regulation of gene transcription
[95], pre-mRNA splicing [96] and protein translation [97].
Transfection-mediated TP53TG1 recovery in HCT116 cells
reduced the level of YBX1 binding of the PI3 K promoter
and, consequently, reduced the abundance of total PI3 K
protein and stabilized p53 protein levels. Interestingly,
hypermethylation of TP53TG1 promoter and YBX1 nuclear
localization in gastric tumour samples were significantly co-
associated with worse progression-free patient survival [84].
MIAT has recently been newly implicated in cancer.
Sattari et al. [87] found that MIAT is upregulated in aggres-
sive forms of chronic lymphocytic leukaemia (CLL). The
study also revealed that MIAT is involved in a positive regu-
latory feedback loop with Oct4, as suppression of one led to
reduced expression of the other [87], consistent with a pre-
vious study that characterized the transcriptional regulation
of MIAT by Oct4 [98]. This MIAT–Oct4 regulatory loop
was also found to directly contribute to apoptosis evasion
in CLL, as repression of either significantly induced cell
death of malignant B cells. Moreover, in an outline of
emerging evidence for the general involvement of the
epigenetic/non-coding interactome in neuroendocrineprostate cancer (NEPC), Crea et al. [88] provided preliminary
evidence showing that MIAT is upregulated in aggressive
NEPC and suggested that it may interact with Polycomb
pathways to promote aggressive disease.
An intriguing cancer-associated example of a splice-
regulatory lncRNA comes in the form of the metastasis-
associated NAT of the gene encoding Zeb2, a transcriptional
repressor of E-cadherin and thus a key metastasis-coordinat-
ing transcription factor. The Zeb2 NAT, known as ZEB2-AS1,
is complementary to the sequence of a large Zeb2 intron con-
taining an internal ribosome entry site that is necessary for its
translation, and expression of this NAT promotes the reten-
tion of this intron in the mRNA by preventing it from
being spliced out of the pre-mRNA, which leads to increased
Zeb2 protein translation [99]. ZEB2-AS1 has recently been
found overexpressed in HCC, and its downregulation in
HCC reduced HCC growth and metastasis. In combination
with HCC patient data analysis linking high ZEB2-AS1
expression levels with worse progression-free survival, this
study indicates its potential utility as an HCC prognosis
biomarker [12].8. Conclusion and perspectives
Unlike genetic defects, epigenetic defects are potentially
reversible and are therefore more amenable to corrective
therapeutic reversal. This realization has driven the rapid
emergence and expansion of epigenetic drug discovery, and
drug-targeting epigenetic enzymes are in the clinic for the
treatment of human disorders, especially for clinical manage-
ment of haematological malignancies and neurological
disorders [13,14]. However, treatments with epi-drugs still
need to overcome the challenge of avoiding off-target effects.
It should be considered that multiple epi-enzymes are
contained in chromatin complexes, and as a result the inhi-
bition of an epigenetic enzyme can result in changes in
other members of the same protein complex. For example,
treatment with the HDAC inhibitor sodium butyrate alters
the acetylation level of histones, but also affects their methyl-
ation status [17]. A new layer of complexity should be taken
into account, because lncRNAs could also be regulated by
epigenetic mechanisms, including CpG methylation as well
as histone marks [21]. The data gathered so far concerning
the involvement of lncRNA in epigenetic regulation are prob-
ably still the tip of the iceberg of this emerging field, and
further expansion of these data may concomitantly reveal a
plethora of as-yet untapped targets and pathways amenable
to epigenetic therapy. Therefore, we should consider the reac-
tivation or silencing of specific lncRNAs after treatment with
epi-drugs and the secondary effects on their target genes.
As summarized in this review, evidence of the deregula-
tion of lncRNAs in human disorders is rapidly increasing and
lncRNAs per se are potential targets of promising therapies.
Several advantages support this research. First, lncRNAs pro-
vide a solution for targeting underexpressed epigenetic
targets. While most epi-drugs produced to date are inhibitors
of epigenetic enzymes, which are effective in mitigating the
aberrant overexpression of epi-enzymes, success in the devel-
opment of small-molecule drugs that are able to induce
protein activation is very scarce. By inhibiting the expression
of any given lncRNA, it is possible to achieve the upregula-




8to short ncRNAs, lncRNA expression shows high specificity,
because they are expressed at different stages of development
and in a cell type-specific manner [23,27]. In addition,
lncRNAs normally target one gene or a small group of related
genes [5], reducing the number of non-specific targets.
Despite the great potential of targeting lncRNAs, the
possibility of manipulating their expression remains largely
unexplored. To date, most efforts have been focused on the
silencing of specific lncRNAs using synthetic ASOs [31].
This is a very interesting strategy to follow in rare disorders
that are normally caused by deficits of specific proteins.
Recently, several ASO-based assays have been reported,
such as the use of ASOs to re-express the paternal Ube3a
allele in Angelman syndrome [34], SCN1A upregulation in
Dravet syndrome [100] or the activation of Frataxin expression
in Friedreich’s ataxia [101]. While ASO-based lncRNA-
targeting strategies are yet to reach clinical trials, MALAT1
has been the best studied lncRNA ASO target in cancer cells
in vitro and hence is currently the most feasible lncRNA
target for the development of an anti-cancer ASO therapeutic
agent [73]. Moreover, if loss of function is caused by epige-
netic silencing, a catalytic domain of an epigenetic enzyme
fused to the CRISPR/Cas system can be used as an epigenetic
editing tool to rewrite the target epigenetic mark at any par-
ticular lncRNA locus to re-express it. On the other hand, an
overexpressed lncRNA could be silenced by reconfiguring
its local chromatin context to repress its expression [102].
Nevertheless, many important questions regarding
lncRNA complexity remain to be solved. Given their biologi-
cal versatility, it is crucial to investigate whether lncRNAs are
activated or silenced in any given tissue, and how they exert
their respective functions. As previously described in this
review, the same lncRNA can participate in several biological
processes such as transcription regulation or formation of
nuclear compartments. We still need to investigate howlncRNA function could be a consequence of external and
internal stimuli.
In summary, the ncRNA world reveals new layers of
complexity in the complex epigenetic milieu. Although we
are beginning to understand their role as chromatin regula-
tors, new functions are steadily emerging. Studies have
revealed lncRNA involvement not only at the transcriptional
level but also in processes such as imprinting, alternative spli-
cing and long-range DNA looping, among others. Just as we
are advancing in our understanding of lncRNA biology, new
lncRNA defects associated with human disorders are being
described, opening new avenues for their uses as disease bio-
markers and/or therapeutic targets. However, the extent of
our current knowledge is greatly limited by methodological
limitations. We still need to make progress on the develop-
ment of appropriate tools to equip researchers to study
lncRNA structure and unravel the spatial and developmental
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